TriangleNCT01057225 · OUTCOME
Progession Free Survival (24 Month)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants at 24 months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 24 months
What was measured
Progression-free survival time is defined as the time from registration to the earliest date of documentation of disease progression. If a patient dies without a documentation of disease progression the patient will be considered to have had disease progression at the time of their death. If the patient is declared to be a major treatment violation, the patient will be censored on the date the treatment violation was declared to have occurred. In the case of a patient starting treatment and then never returning for any evaluations, the patient will be censored for progression 1 day post-registration. This is reported as the percentage of patients alive and progression free at the 24 month mark.
Analysis population: All of the 64 participants that were eligible and began treatment were evaluated.
Groups in this outcome
All Treated Patients
Patients receive carfilzomib IV on days 1, 2, 8, 9, 15, and 16; oral cyclophosphamide on days 1, 8, and 15; oral dexamethasone on days 1, 8, 15, and 22; and oral thalidomide on days 1-28.
| Group | Source count |
|---|---|
| All Treated Patients | 64 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| All Treated Patients | 76 | Not reported | 59 | 87 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 59
- upper Limit
- 87
- value
- 76
- denoms
- counts
- group Id
- OG000
- value
- 64
- units
- Participants
- description
- Progression-free survival time is defined as the time from registration to the earliest date of documentation of disease progression. If a patient dies without a documentation of disease progression the patient will be considered to have had disease progression at the time of their death. If the patient is declared to be a major treatment violation, the patient will be censored on the date the treatment violation was declared to have occurred. In the case of a patient starting treatment and then never returning for any evaluations, the patient will be censored for progression 1 day post-registration. This is reported as the percentage of patients alive and progression free at the 24 month mark.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receive carfilzomib IV on days 1, 2, 8, 9, 15, and 16; oral cyclophosphamide on days 1, 8, and 15; oral dexamethasone on days 1, 8, 15, and 22; and oral thalidomide on days 1-28.
- id
- OG000
- title
- All Treated Patients
- param Type
- NUMBER
- population Description
- All of the 64 participants that were eligible and began treatment were evaluated.
- reporting Status
- POSTED
- time Frame
- 24 months
- title
- Progession Free Survival (24 Month)
- type
- SECONDARY
- unit Of Measure
- percentage of participants at 24 months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice